Recent News

• 05.06.2025 - Heron Therapeutics Q1 2025 Conference Call
• 05.06.2025 - Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
• 05.06.2025 - Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
• 04.28.2025 - Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
• 04.22.2025 - Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Recent Filings

• 05.06.2025 - 8-K Current report
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 8-K Current report
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material